Renaissance Technologies LLC Grows Stake in Omada Health, Inc. $OMDA

Renaissance Technologies LLC increased its stake in shares of Omada Health, Inc. (NASDAQ:OMDA) by 173.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 391,069 shares of the company’s stock after purchasing an additional 248,269 shares during the period. Renaissance Technologies LLC owned 0.66% of Omada Health worth $4,916,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of Omada Health during the 2nd quarter worth approximately $32,000. Bellevue Group AG grew its stake in shares of Omada Health by 0.7% in the 3rd quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock valued at $5,567,000 after buying an additional 1,791 shares during the period. Quarry LP acquired a new stake in shares of Omada Health during the 4th quarter worth approximately $29,000. Barclays PLC increased its holdings in shares of Omada Health by 14.6% during the 4th quarter. Barclays PLC now owns 14,850 shares of the company’s stock worth $234,000 after buying an additional 1,888 shares during the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new stake in shares of Omada Health during the 4th quarter valued at approximately $32,000.

More Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Quarterly results beat expectations. Omada reported adjusted earnings of $0.15 per share, up from a $0.09 loss a year earlier and above the $0.05 consensus estimate. Another earnings summary reported EPS of $0.08 versus an expected loss of $0.02, reinforcing that results exceeded forecasts. Omada Health Q2 earnings and revenues top estimates
• Positive Sentiment: Growth remained strong. Second-quarter revenue rose 43% year over year, while total members increased 45%. Gross margin also reached a new quarterly record, supporting the company’s growth and profitability narrative. Omada Health reports second-quarter 2026 results
• Positive Sentiment: Full-year revenue guidance exceeded Wall Street expectations. Omada forecast fiscal 2026 revenue of $334 million to $340 million, above the $327.2 million analyst consensus. This suggests management expects sustained demand for its digital chronic-care programs.
• Neutral Sentiment: Leadership transition adds an execution consideration. Co-founder and CEO Sean Duffy will become executive chair on January 1, 2027, while President Wei-Li Shao becomes CEO. The planned, internal succession may provide continuity, although investors will monitor whether the change affects growth execution.
• Negative Sentiment: CEO insider selling provided a modest counterpoint. Duffy sold 12,944 shares for approximately $264,000, reducing his direct ownership by 3.05%. While the sale may have been for personal or financial-planning reasons, insider selling can weigh on sentiment.

Analyst Ratings Changes

Several research firms have issued reports on OMDA. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of Omada Health in a research note on Friday, May 8th. Evercore reiterated an “outperform” rating and set a $20.00 price target on shares of Omada Health in a report on Friday, May 8th. Citigroup reissued an “outperform” rating on shares of Omada Health in a research report on Monday, July 20th. Wells Fargo & Company upped their target price on shares of Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Finally, Canaccord Genuity Group lifted their price target on shares of Omada Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Omada Health has a consensus rating of “Moderate Buy” and a consensus target price of $24.75.

Insider Buying and Selling

In other Omada Health news, CFO Steven L. Cook sold 33,000 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $19.89, for a total transaction of $656,370.00. Following the completion of the transaction, the chief financial officer owned 133,359 shares in the company, valued at $2,652,510.51. The trade was a 19.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Craig Gracey sold 6,894 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $17.42, for a total transaction of $120,093.48. Following the completion of the sale, the chief accounting officer directly owned 9,191 shares in the company, valued at approximately $160,107.22. This represents a 42.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 206,406 shares of company stock worth $4,191,483 over the last 90 days. 6.38% of the stock is owned by insiders.

Omada Health Price Performance

Shares of NASDAQ OMDA opened at $19.54 on Friday. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -72.37 and a beta of 1.73. The stock’s 50-day moving average is $20.24 and its two-hundred day moving average is $16.15. Omada Health, Inc. has a 1-year low of $10.28 and a 1-year high of $26.92.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.10. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. Equities research analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Omada Health Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.